CPMV-DOX delivers
Alaa A A Aljabali1, Sourabh Shukla, George P Lomonossoff
1Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK.
Molecular Pharmaceutics
|July 26, 2012
Summary
Cowpea mosaic virus (CPMV) acts as a novel drug carrier for doxorubicin (DOX). The CPMV-DOX conjugate demonstrates enhanced cancer cell killing and targeted drug release, showcasing CPMV's potential in drug delivery.
Area of Science:
- Biotechnology
- Nanomedicine
- Virology
Background:
- Cowpea mosaic virus (CPMV) is a plant virus with potential applications in nanomedicine.
- Doxorubicin (DOX) is a widely used chemotherapeutic agent with limitations in targeted delivery.
- Viral nanoparticles (VNPs) offer unique properties for drug conjugation and delivery.
Purpose of the Study:
- To develop and evaluate Cowpea mosaic virus (CPMV) as a drug delivery vehicle for the chemotherapeutic drug doxorubicin (DOX).
- To assess the cytotoxicity and cellular uptake of the CPMV-DOX conjugate compared to free DOX.
- To investigate the drug release mechanism and cellular targeting of the CPMV-DOX conjugate.
Main Methods:
- Covalent conjugation of eighty DOX molecules to the external surface carboxylates of CPMV nanoparticles.
- In vitro cytotoxicity assays using HeLa cells to compare CPMV-DOX with free DOX at varying concentrations.
- Cellular uptake studies to determine the endolysosomal targeting of the CPMV-DOX conjugate.
Main Results:
- CPMV-DOX conjugate exhibited greater cytotoxicity than free DOX at low dosages.
- Higher concentrations of CPMV-DOX showed a time-delayed cytotoxicity effect.
- The CPMV conjugate was effectively targeted to the endolysosomal compartment for drug release.
Conclusions:
- CPMV serves as a viable and effective nanoparticle carrier for doxorubicin delivery.
- The CPMV-DOX conjugate demonstrates improved therapeutic potential through enhanced cytotoxicity and targeted release.
- This study establishes the utility of CPMV as a novel drug delivery platform in nanomedicine.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:28Diphtheria
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...